UNSPSC 51373338: Hydrocodone/ibuprofen

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN101. This VA Drug Class (CN101) classifies this compound as belonging to the group OPIOID ANALGESICS.

UNSPSC 51373338 Hydrocodone/ibuprofen is a Commodity code that in practice covers pharmaceutical product procurement by state and local health agencies, though the recent opportunities tagged to this code show limited direct activity aligned with the specific combination product itself. State and local health departments, county health systems, cooperative purchasing alliances, and state human services commissions solicit pharmaceuticals and related health commodities under this classification, typically as part of broader health initiative procurement or pharmacy benefit programs. The work involves acquiring finished pharmaceutical products through competitive bidding, establishing framework agreements with manufacturers and wholesalers, and managing direct-to-manufacturer or group purchasing relationships to support community health services and state employee benefits.

Recent opportunities demonstrate the breadth of pharmaceutical procurement under the code's broader tier. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through competitive sealed bidding, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, released an RFP in January 2026 (due March 26, 2026) establishing multiple contracts for generic multi-source pharmaceuticals and OTC products to be distributed across participating state and local government facilities in Minnesota, Oregon, and other member jurisdictions through three authorized wholesalers. The Texas Health and Human Services Commission issued RFI HHS0017013 in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling state intent to develop direct contracting relationships outside traditional pharmacy benefit manager and group purchasing organization channels. Activity spans Florida, Minnesota, Oregon, and Texas, with cooperative purchasing vehicles and state human services agencies as primary issuing bodies.